These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9129692)

  • 1. Progress in clinical chemoprevention.
    Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
    Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
    Crowell JA
    Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of chemoprevention in cancer control.
    Greenwald P; Kelloff GJ
    IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic considerations in the evaluation of chemopreventive data.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC
    IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evidence-based approach to cancer prevention clinical trials.
    Greenwald P; McDonald SS; Anderson DE
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S43-7. PubMed ID: 12570334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micronutrients as chemopreventive agents.
    Reddy BS
    IARC Sci Publ; 1996; (139):221-35. PubMed ID: 8923033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.
    Scott EN; Gescher AJ; Steward WP; Brown K
    Cancer Prev Res (Phila); 2009 Jun; 2(6):525-30. PubMed ID: 19470784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.
    Johnson KA; Beitz J; Justice R; Schmidt W; Andrews P; DeLap R
    J Cell Biochem Suppl; 1997; 27():1-6. PubMed ID: 9591186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The advancement of cancer chemoprevention by revision of clinical trial strategies.
    Sharma RA
    Panminerva Med; 2002 Mar; 44(1):41-5. PubMed ID: 11887091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and surrogacy: relevance to chemoprevention.
    Kensler TW; Davidson NE; Groopman JD; Muñoz A
    IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer prevention: recent progress and future opportunities.
    Weinstein IB
    Cancer Res; 1991 Sep; 51(18 Suppl):5080s-5085s. PubMed ID: 1884384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.